Natixis Advisors, L.P. Intra Cellular Therapies, Inc. Transaction History

Natixis Advisors, L.P.

$51.3 Billion
Q3 2024

A detailed history of Natixis Advisors, L.P. transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Natixis Advisors, L.P. holds 24,583 shares of ITCI stock, worth $2.14 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

24,583

Previous 31,660 22.35%

Holding current value

$2.14 Million

Previous $2.17 Million 17.02%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$67.99 - $80.84 $481,165 - $572,104	-7,077 Reduced 22.35%	24,583 $1.8 Million
Q2 2024 Aug 01, 2024	SELL	$64.76 - $79.84 $232,617 - $286,785	-3,592 Reduced 10.19%	31,660 $2.17 Million
Q1 2024 Apr 25, 2024	BUY	$64.37 - $75.65 $87,800 - $103,186	1,364 Added 4.03%	35,252 $2.44 Million
Q4 2023 Feb 06, 2024	BUY	$46.37 - $73.65 $118,428 - $188,102	2,554 Added 8.15%	33,888 $2.43 Million
Q3 2023 Nov 13, 2023	SELL	$52.09 - $64.1 $130,745 - $160,891	-2,510 Reduced 7.42%	31,334 $1.63 Million
Q2 2023 Aug 15, 2023	BUY	$54.67 - $66.44 $349,067 - $424,219	6,385 Added 23.25%	33,844 $2.14 Million
Q1 2023 May 11, 2023	BUY	$43.8 - $56.99 $481 - $626	11 Added 0.04%	27,459 $1.49 Million
Q4 2022 Jan 27, 2023	BUY	$44.07 - $54.45 $283,898 - $350,766	6,442 Added 30.67%	27,448 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$42.7 - $59.99 $89,627 - $125,919	2,099 Added 11.1%	21,006 $977,000
Q2 2022 Aug 12, 2022	BUY	$43.0 - $65.64 $31,906 - $48,704	742 Added 4.08%	18,907 $1.08 Million
Q1 2022 May 12, 2022	BUY	$38.74 - $62.09 $292,796 - $469,276	7,558 Added 71.25%	18,165 $1.11 Million
Q4 2021 Feb 08, 2022	BUY	$35.2 - $53.42 $373,366 - $566,625	10,607 New	10,607 $555,000
Q1 2021 May 05, 2021	SELL	$30.8 - $39.51 $331,346 - $425,048	-10,758 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$23.34 - $32.22 $251,091 - $346,622	10,758 New	10,758 $342,000

Others Institutions Holding ITCI

# of Institutions

378

Shares Held

84.7M

Call Options Held

319K

Put Options Held

143K

View Full List

About Intra-Cellular Therapies, Inc.

Ticker ITCI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 94,401,696
Market Cap $8.21B
Description
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...

More about ITCI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Natixis Advisors, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Natixis Advisors, L.P. with notifications on news.

Account

Natixis Advisors, L.P. Intra Cellular Therapies, Inc. Transaction History